Rules Based Medicine
Rules Based Medicine is recorded as a service provider in 64 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 64 trials · Latest update first
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
Sponsor Mediar Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A parallel group, Phase 3, randomized, open-label, 2-arm study to demonstrate the superiority of belumosudil versus best available therapy (BAT) in participants at least 12 years of age with chronic graft versus host disease (cGVHD) refractory to or recurrent after 2 to 5 prior lines of systemic therapy
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 2b, Multicenter, Randomized, Double-blind Induction, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Crohn’s Disease
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer
Sponsor Xencor Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- Twenty-two clinical sites enrolled subjects across Belgium, Greece, Malaysia, the Netherlands, Portugal, Spain, Taiwan, and the United States.
- After review of data from the first two subjects enrolled at 750 mg, the IMC modified Part 1 randomization so that subsequently enrolled subjects received either 500 mg or 750 mg.
- After reviewing 28 randomized and treated Part 1 subjects, the IMC recommended ending enrollment and not initiating Part 2.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)
Sponsor Corcept Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with PD-L1 ≥ 50%
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 48-week SAR448851 treatment followed by open-label extension in participants with early Alzheimer’s disease.
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
Efficacy, safety, and pharmacokinetics of NNC0519-0130 once weekly s.c. versus semaglutide 1.0 mg and placebo in people with chronic kidney disease, with or without type 2 diabetes, and with overweight or obesity: a proof-of-concept and dose-finding study
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, parallel group, placebo-controlled multicenter study to evaluate efficacy, safety and tolerability of ianalumab in participants with diffuse cutaneous systemic sclerosis
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Dose Comparison and Exploratory Efficacy Study of Orally Administered SAT-3247 in Ambulatory DMD Patients
Sponsor Satellos Bioscience Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Dose Levels of ESK-001 in Adult Patients with Systemic Lupus Erythematosus
Sponsor Alumis Inc.
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, placebo-controlled, parallel-group, 52-week Phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in adult participants with inadequately-controlled chronic rhinosinusitis with nasal polyps
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc)
Sponsor Boehringer Ingelheim International GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, placebo-controlled, parallel-group, Proof-of-Concept (PoC) study to assess the efficacy, safety and tolerability of itepekimab, in participants with non-cystic fibrosis bronchiectasis
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- The study enrolled 314 participants at 117 sites in 20 countries between 20 February 2024 and 7 March 2025.
- Of 386 screened participants, 72 were screen failures because they did not meet eligibility criteria.
- A January 2024 protocol amendment revised the pulmonary-exacerbation endpoint definition following health-authority feedback and added adjudication of moderate or severe pulmonary exacerbations.
- Few scheduled site visits for sample collection were missed, and only participants with data at the specified time points were reported for spirometry and pharmacokinetic analyses.
These findings describe the trial, not the service provider’s performance or responsibility.
An Open-Label Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors
Sponsor Eisai Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE-791 in Subjects with Idiopathic Pulmonary Fibrosis
Sponsor Contineum Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination with Ipilimumab or Cabozantinib in Participants with Advanced Renal Cell Carcinoma (RCC)
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Not reported
- Latest update
- Estimated end
ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination with Ipilimumab in Participants with First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Rules Based Medicine?
The 2026-10-09 snapshot links Rules Based Medicine to 64 distinct CTIS trials. Recorded services include Laboratory services, Ancillary lab, Biomarker Measurement, Chemokines/Cytokines, among 19 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Rules Based Medicine?
The most frequently recorded therapeutic areas are Immunology, Solid Tumor Oncology, Respiratory, Rheumatology. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Rules Based Medicine conducted?
The linked trials record locations in 24 countries, including Spain, Poland, Italy, France, Germany. These are trial locations, not confirmed office locations or countries where Rules Based Medicine delivered services.
What can this page tell me about Rules Based Medicine's trial experience?
Browse 64 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 2 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Rules Based Medicine. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Rules Based Medicine Inc.
- Rules-Based Medicine